Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.46 |
| ▸ | MAPKAPK2 | P49137 | 6/20 | 0.45 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.42 |
| ▸ | RORC | P51449 | 4/20 | 0.41 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.41 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | BRAF | P15056 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30177374 | 1.00 | NAMPT (0.46) | NAMPTMAPKAPK2CYP17A1RORCEGLN2 | |
| SCHEMBL31363779 | 0.84 | NAMPT (0.51) | NAMPTMAPKAPK2CYP17A1RORCPSMB8 | |
| SCHEMBL26627940 | 0.83 | BRAF (0.45) | RORCBRAFCYP2C9 | |
| SCHEMBL5778192 | 0.82 | NAMPT (0.49) | NAMPTMAPKAPK2CYP17A1RORCPSMB8 | |
| SCHEMBL30884737 | 0.82 | NAMPT (0.49) | NAMPTMAPKAPK2CYP17A1RORCPSMB8 | |
| SCHEMBL6452120 | 0.81 | AR (0.59) | NAMPTMAPKAPK2CYP17A1EGLN2PSMB8 | |
| SCHEMBL29636441 | 0.81 | AR (0.59) | NAMPTMAPKAPK2CYP17A1EGLN2PSMB8 | |
| SCHEMBL20934804 | 0.80 | NAMPT (0.47) | NAMPTMAPKAPK2CYP17A1RORCPSMB8 | |
| SCHEMBL1463135 | 0.80 | NAMPT (0.47) | NAMPTMAPKAPK2CYP17A1RORCPSMB8 | |
| SCHEMBL1812057 | 0.79 | NAMPT (0.51) | NAMPTMAPKAPK2CYP17A1PSMB8MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11807644-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-11807644-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-20230002403-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2023-01-05 | — | — | US | disclosed |
| US-20220213062-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2022-07-07 | — | — | US | disclosed |
| US-11339141-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| WO-2021231474-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. (US) | 2021-11-18 | — | — | WO | disclosed |
| US-20210002252-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2021-01-07 | — | — | US | disclosed |
| US-10640485-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS, INC. (US) | 2020-05-05 | — | — | US | disclosed |
| US-20190119249-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2019-04-25 | — | — | US | disclosed |
| EP-3416638-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV Pharmaceuticals, Inc. (US) | 2018-12-26 | — | — | EP | disclosed |
| CN-109069481-A | Methods and compounds for restoring function of mutant p53 | 皮姆维制药公司 | 2018-12-21 | — | — | CN | disclosed |
| US-10138219-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS (US) | 2018-11-27 | — | — | US | disclosed |
| US-20170240525-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2017-08-24 | — | — | US | disclosed |
| WO-2017143291-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. (US) | 2017-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170240525-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, KRAS | NAMPT 2431/4885MAPKAPK2 1336/4885CYP17A1 2984/4885 |
| US-11339141-B2 | Methods and compounds for restoring mutant p53 function | TP53, TP53BP1, KRAS | NAMPT 2431/4885MAPKAPK2 1336/4885CYP17A1 2984/4885 |
| US-20220213062-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, KRAS | NAMPT 2431/4885MAPKAPK2 1336/4885CYP17A1 2984/4885 |
| US-20230002403-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, HRAS | NAMPT 2265/4885MAPKAPK2 938/4885CYP17A1 3594/4885 |
| US-20190119249-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, KRAS | NAMPT 2431/4885MAPKAPK2 1336/4885CYP17A1 2984/4885 |
| US-11807644-B2 | Methods and compounds for restoring mutant p53 function | TP53, TP53BP1, HRAS | NAMPT 2265/4885MAPKAPK2 938/4885CYP17A1 3594/4885 |
| US-10640485-B2 | Methods and compounds for restoring mutant p53 function | TP53, TP53BP1, KRAS | NAMPT 2431/4885MAPKAPK2 1336/4885CYP17A1 2984/4885 |
| US-20210002252-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, KRAS | NAMPT 2431/4885MAPKAPK2 1336/4885CYP17A1 2984/4885 |
| US-10138219-B2 | Methods and compounds for restoring mutant p53 function | TP53, TP53BP1, KRAS | NAMPT 2431/4885MAPKAPK2 1336/4885CYP17A1 2984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.